PAX6 and renal cell carcinoma: Specifically, SNHG17 upregulates PAX6 to facilitate the development of oral squamous cell carcinoma [25], stimulates SOX4 to promote the epithelial-mesenchymal transition in ESCC cells [26], and activates H2AX-associated signaling pathways to promote the development of renal cell carcinoma [27].